Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parrondo

Showing results (191-200 of 234) with videos related to

Pageof 24
Sort By:
British Journal of Haematology|October 26, 2021
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemiaZaid H Abdel Rahman, Ricardo D Parrondo, Michael G Heckman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Zi Chen, Bo Huang, et al.
American Journal of Hematology|February 25, 2026
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and DexamethasoneRicardo D Parrondo, Ricardo C B de Menezes, Hanna Sledge, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Transplantation and Cellular Therapy|November 15, 2021
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell TransplantationSurbhi Sidana, Shaji Kumar, Raphael Fraser, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Advances|October 15, 2025
AL Amyloidosis: A Real-World Experience with CAR-T Cell TherapyMelinda Sy Tan, Rahma Warsame, Ricardo D Parrondo, et al.
Pageof 24

Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
British Journal of Haematology|October 26, 2021
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemiaZaid H Abdel Rahman, Ricardo D Parrondo, Michael G Heckman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Zi Chen, Bo Huang, et al.
American Journal of Hematology|February 25, 2026
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and DexamethasoneRicardo D Parrondo, Ricardo C B de Menezes, Hanna Sledge, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 29, 2025
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple MyelomaMatthew J Rees, Timothy T Xu, Suheil Albert Atallah-Yunes, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Transplantation and Cellular Therapy|November 15, 2021
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell TransplantationSurbhi Sidana, Shaji Kumar, Raphael Fraser, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Advances|October 15, 2025
AL Amyloidosis: A Real-World Experience with CAR-T Cell TherapyMelinda Sy Tan, Rahma Warsame, Ricardo D Parrondo, et al.
Pageof 24